Sorrento Therapeutics Inc SRNE:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:36 AM EST
1.01UNCH (UNCH)
Volume
21,825
Close
1.01quote price arrow up+0.05 (+5.21%)
Volume
10,998,197
52 week range
0.74 - 3.60
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.01
  • 52 Week High3.60
  • 52 Week High Date02/09/22
  • 52 Week Low0.74
  • 52 Week Low Date12/22/22

Key Stats

  • Market Cap476.599M
  • Shares Out471.88M
  • 10 Day Average Volume11.67M
  • Dividend-
  • Dividend Yield-
  • Beta1.95
  • YTD % Change14

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.01
  • 52 Week High3.60
  • 52 Week High Date02/09/22
  • 52 Week Low0.74
  • 52 Week Low Date12/22/22
  • Market Cap476.599M
  • Shares Out471.88M
  • 10 Day Average Volume11.67M
  • Dividend-
  • Dividend Yield-
  • Beta1.95
  • YTD % Change14

RATIOS/PROFITABILITY

  • EPS (TTM)-1.33
  • P/E (TTM)-0.76
  • Fwd P/E (NTM)-4.39
  • EBITDA (TTM)-345.765M
  • ROE (TTM)-374.84%
  • Revenue (TTM)60.322M
  • Gross Margin (TTM)62.09%
  • Net Margin (TTM)-821.69%
  • Debt To Equity (MRQ)53.63%

EVENTS

  • Earnings Date03/03/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sorrento Therapeutics Inc

 

Profile

MORE
Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management...
Henry Ji Ph.D.
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
Elizabeth Czerepak
Chief Financial Officer, Executive Vice President
Address
4955 Directors Place
San Diego, CA
92121
United States

Top Peers

SYMBOLLASTCHG%CHG
NGM
NGM Biopharmaceuticals Inc
5.09-0.09-1.74%
TSVT
2Seventy Bio Inc
13.25+0.37+2.87%
ATRA
Atara Biotherapeutics Inc
5.27+0.33+6.68%
STRO
Sutro Biopharma Inc
7.50+0.01+0.13%
CCCC
C4 Therapeutics Inc
7.84+0.18+2.35%